Expanding the one-stop CDMO business using CLiC-1
First written in FY2023. 10 of 13 entries say "Advanced", first in FY2024-Q2. Latest entry: 2026-08-13.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「CDMO and consulting services 210,159 25.4」
Full-year revenue from CDMO and consulting services was ¥210.159 million, up 25.4% year on year. Capital investment and supply-capacity expansion using the regenerative CDMO subsidy also continued. - FY2026-H1AdvancedAnnual report
「During the interim consolidated accounting period under review, we applied for the FY2024 supplementary-budget subsidy for the “Regenerative, Cellular and Gene Therapy Manufacturing Equipment Support Project,” a Ministry of Economy, Trade and Industry program, and were selected under the “New Technology Introduction Promotion” category. The project aims to secure domestic capacity to manufacture regenerative, cellular and gene therapy products smoothly, strengthen Japan’s drug-discovery capabilities, and develop contract manufacturing of such products into an export industry. We will use the subsidy for capital investment and other purposes to increase supply capacity in the CDMO business.」
The company was selected under the New Technology Introduction Promotion category of the regenerative CDMO subsidy program and advanced concrete measures to increase CDMO supply capacity through capital investment. Interim revenue from CDMO and consulting services was ¥192.705 million, up from ¥7.893 million in the same interim period of the previous year. - FY2025AdvancedAnnual report
「CDMO and consulting services 167,605 625.5」
Full-year revenue from CDMO and consulting services was ¥167.605 million, up 625.5% year on year, significantly increasing the contract-business track record. - FY2025-H1AdvancedAnnual report
「As a result, business performance for the interim consolidated accounting period under review was revenue of ¥7.893 million, an operating loss of ¥398.694 million, an ordinary loss of ¥464.369 million and an interim net loss attributable to owners of the parent of ¥466.176 million.」
Revenue from CDMO and consulting services was ¥7.893 million for the interim consolidated accounting period, adding to the contract-service track record. - FY2024AdvancedAnnual report
「Revenue included revenue from contract manufacturing and development services (CDMO services). As a result, business performance for the consolidated fiscal year under review was revenue of ¥23.102 million, an operating loss of ¥588.487 million, an ordinary loss of ¥627.930 million and a net loss attributable to owners of the parent of ¥632.183 million.」
Full-year revenue from CDMO and consulting services was ¥23.102 million, building on cumulative revenue of ¥15.098 million in the previous quarter. - FY2024-Q3AdvancedAnnual report
「Revenue included revenue from contract manufacturing and development services (CDMO services). As a result, business performance for the cumulative third-quarter period under review was revenue of ¥15.098 million, an operating loss of ¥461.297 million, an ordinary loss of ¥500.601 million and a quarterly net loss attributable to owners of the parent of ¥503.959 million.」
Revenue including CDMO services increased from ¥11.772 million for the cumulative second-quarter period to ¥15.098 million for the cumulative third-quarter period, reflecting accumulated contract-service revenue. - FY2024-Q2AdvancedAnnual report
「Revenue included revenue from contract manufacturing and development services (CDMO services). As a result, business performance for the cumulative second-quarter period under review was revenue of ¥11.772 million, an operating loss of ¥290.155 million, an ordinary loss of ¥328.071 million and a quarterly net loss of ¥327.575 million.」
CDMO service revenue totaled ¥11.772 million for the cumulative second-quarter period, building on the previous quarter’s results. - FY2024-Q1RestatedAnnual report
「Revenue included revenue from contract manufacturing and development services (CDMO services). We also proceeded with discussions with customers and preparations for the operating system for multiple contracts scheduled to begin in the second quarter.」
CDMO service revenue of ¥3.900 million was recorded in the quarter, while customer discussions and operating preparations proceeded for multiple contracts scheduled to begin in the second quarter. - FY2023First statedAnnual report
「This enables us to handle the entire process on a one-stop basis, from manufacturing-process development through nonclinical and clinical trials to commercial production.」
CLiC-1, which includes laboratory facilities, enables detailed services that also accommodate small-volume production. CDMO and consulting revenue was ¥38.278 million, up 175.1% year on year.